• No results found

!"#$!%&'"()$*+",$-'+./$012+3%45"%$6%1).'7'8+%/$ 0..'5.1%9%.2$:$09;7+<+1(2+'.$=5+>%7+.%/$

N/A
N/A
Protected

Academic year: 2021

Share "!"#$!%&'"()$*+",$-'+./$012+3%45"%$6%1).'7'8+%/$ 0..'5.1%9%.2$:$09;7+<+1(2+'.$=5+>%7+.%/$"

Copied!
11
0
0

Loading.... (view fulltext now)

Full text

(1)

!"#$%&'()&*+&",-./.01*2*3)4*3&5.)6,*7$)8*!--.(-"&9&-#*:*!9;/$<$"6#$.-*=($>&*?*@A@B*

*

!"#$%&'()&*+&",-./.0$&C* ****************************************************************************************B* ************************* ** D6)",*@A@B*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

!"#$!%&'"()$*+",$-'+./$012+3%45"%$6%1).'7'8+%/$

0..'5.1%9%.2$:$09;7+<+1(2+'.$=5+>%7+.%/$

*

*

*

*

* *

*

?'995.+1(2+'.$6''7/*

(2)
(3)

!"#$%&'()&*+&",-./.01*2*3)4*3&5.)6,*7$)8*!--.(-"&9&-#*:*!9;/$<$"6#$.-*=($>&*?*@A@B*

*

!"#$%&'()&*+&",-./.0$&C* ****************************************************************************************Q* ************************* ** D6)",*@A@B*

*

!"#$%&'%(#)%(*+,#"-%./#0%./,%"12%344#,5*2%6*"27-,$%

!"#$!%&'"()$*+",@$?)+%<$A%>+1(7$(.>$B1+%.1%$0>3+/'"$

3&5.)6,*Y4*7$)8F*D3*$C*6*M.)/>2)&-.M-&>*9&>$"6/*;,1C$"$6-*6->*&8;&)#*.-*JGW[!G3H*6->*$-<&"#$.(C*>$C&6C&C*6->*6*>$;/.96#*M,.*C&)%&>*6C*6*C;&"$6/*)&;)&C&-#6#$%&*

<.)*0/.56/*,&6/#,*>$;/.96"14*D.C#*)&"&-#/1F*7$)8*C&)%&>*.-*#,&*E,$#&*J.(C&*I.).-6%$)(C*+6CN*\.)"&*<).9*\&54*@A@A*#.*]6-4*@A@B4*J&)*#,)&&2>&"6>&2/.-0*"6)&&)*,6C*

<."(C&>*.-*JGW[!G3H*$99(-./.01F*%6""$-&*)&C&6)",F*6->*0/.56/*,&6/#,4*!C*#,&*^4H4*=/.56/*!G3H*I..)>$-6#.)*<.)*;)&C$>&-#C*76)6"N*L5696*6->*3.-6/>*+)(9;F*7$)8*

.%&)C6M*#,&*$9;/&9&-#6#$.-*.<*#,&*^4H4*')&C$>&-#_C*R9&)0&-"1*'/6-*<.)*!G3H*P&/$&<*S'R'\!PTF*#,&*/6)0&C#*".99$#9&-#*51*6-1*-6#$.-*#.*".956#*6*C$-0/&*>$C&6C&*$-*

,$C#.)1F*6C*M&//*6C*6//*^4H4*0.%&)-9&-#*&-060&9&-#*M$#,*#,&*=/.56/*\(->*#.*\$0,#*!G3HF*+(5&)"(/.C$CF*6->*D6/6)$64*H&)%$-0*6C*#,&*^4H4*H;&"$6/*P&;)&C&-#6#$%&*<.)*

=/.56/*J&6/#,*3$;/.96"1F*C,&*6/$0-&>*#,&*^4H4*=.%&)-9&-#_C*>$;/.96"1*M$#,*<.)&$0-*6CC$C#6-"&*;).0)69C*#,6#*6>>)&CC*0/.56/*,&6/#,*",6//&-0&C*6->*6""&/&)6#&*

;).0)&CC*#.M6)>*6",$&%$-0*6-*!G3H2<)&&*0&-&)6#$.-`*&->$-0*;)&%&-#65/&*",$/>*6->*96#&)-6/*>&6#,C`*6->*;)&%&-#$-0F*>&#&"#$-0F*6->*)&C;.->$-0*#.*$-<&"#$.(C*>$C&6C&*

#,)&6#C4*

G-*BabVF*7$)8*5&06-*,&)*"6)&&)*M$#,*#,&*3&;6)#9&-#*.<*3&<&-C&*S3.3T*6C*6*9$/$#6)12#)6$-&>*"/$-$"$6-*$-*$99(-./.01F*<."(C$-0*.-*JGW[!G3H*%6""$-&*)&C&6)",4*\).9*

BabV2Baba*C,&*C&)%&>*6C*6-*!CC$C#6-#*I,$&<*.<*#,&*J.C;$#6/*G99(-./.01*H&)%$"&*6#*E6/#&)*P&&>*!)91*D&>$"6/*I&-#&)4*+,).(0,*,&)*;).<&CC$.-6/$C9*6->*/&6>&)C,$;*

$-*#,&*<$&/>F*C,&*C&)%&>*6C*#,&*3$)&"#.)*.<*#,&*^4H4*D$/$#6)1*JGW*P&C&6)",*').0)69*S^HDJP'T*6#*#,&*E6/#&)*P&&>*!)91*G-C#$#(#&*.<*P&C&6)",*<).9*BaaX2@AAV4*7$)8*

,&/;&>*/&6>*.-&*.<*#,&*9.C#*$-</(&-#$6/*JGW*%6""$-&*#)$6/C*$-*,$C#.)1*SN-.M-*6C*PW*BUUF*.)*#,&*+,6$*#)$6/TF*M,$",*;).%$>&>*#,&*<$)C#*C(;;.)#$-0*&%$>&-"&*.<*6-1*%6""$-&_C*

;.#&-#$6/*&<<&"#$%&-&CC*$-*;)&%&-#$-0*JGW*$-<&"#$.-4*3()$-0*#,$C*#$9&F*C,&*6/C.*).C&*#.*#,&*)6-N*.<*I./.-&/F*5)$-0$-0*#.0&#,&)*#,&*Z6%1F*!)91F*6->*!$)*\.)"&*$-*6*-&M*

9.>&/*.<*"..;&)6#$.-*?*$-")&6C$-0*#,&*&<<$"$&-"1*6->*&<<&"#$%&-&CC*.<*#,&*^4H4*9$/$#6)1_C*JGW[!G3H*&<<.)#C*#,).(0,*$-#&)26->*$-#)6260&-"1*".//65.)6#$.-4*+,&-*N-.M-*

6C*I./.-&/*7$)8F*C,&*M6C*6M6)>&>*#M.*;)&C#$0$.(C*^4H4*D&)$#.)$.(C*H&)%$"&*D&>6/C*6->*#,&*Y&0$.-*.<*D&)$#*!M6)>*<.)*,&)*0).(->5)&6N$-0*)&C&6)",F*/&6>&)C,$;*6->*

96-60&9&-#*CN$//C*>()$-0*,&)*#&-()&*6#*3.34*

\).9*@AAV2@ABUF*7$)8*C&)%&>*6C*#,&*3$)&"#.)*.<*#,&*I&-#&)C*<.)*3$C&6C&*I.-#)./*6->*')&%&-#$.-cC*SI3IT*3$%$C$.-*.<*=/.56/*JGW[!G3H*S3=J!T*$-*#,&*I3I*I&-#&)*<.)*

=/.56/*J&6/#,4*!C*3=J!*3$)&"#.)F*C,&*(#$/$d&>*,&)*/&6>&)C,$;*65$/$#1F*C(;&)$.)*#&",-$"6/*CN$//CF*6->*;6CC$.-*#.*6",$&%&*#)&9&->.(C*,&6/#,*$9;6"#4*H,&*C(""&CC<(//1*

/&>*#,&*$9;/&9&-#6#$.-*.<*I3I_C*'R'\!P*;).0)69C*6).(->*#,&*M.)/>*6->*96-60&>*6-*6--(6/*5(>0&#*.<*9.)&*#,6-*eB4V*5$//$.-4*7$)8*M6C*)&C;.-C$5/&*<.)*6//*.<*#,&*

60&-"1cC*0/.56/*JGW[!G3H*6"#$%$#$&CF*$-"/(>$-0*;).%$>$-0*.%&)C$0,#*#.*9.)&*#,6-*UAA*C#6<<*6#*,&6>f(6)#&)CF*.%&)*BFVAA*C#6<<*$-*#,&*<$&/>F*6->*9.)&*#,6-*UV*".(-#)1*

6->*)&0$.-6/*.<<$"&C*$-*!<)$"6F*!C$6F*#,&*I6)$55&6-F*6->*Y6#$-*!9&)$"64*P&".0-$d&>*<.)*,&)*>$C#$-0($C,&>*6->*>&>$"6#&>*".99$#9&-#*#.*5($/>$-0*/."6/*"6;6"$#1*6->*

C#)&-0#,&-$-0*f(6/$#1*/65.)6#.)1*,&6/#,*C&)%$"&C*6->*C1C#&9C*$-*!<)$"6F*$-*@ABBF*7$)8*)&"&$%&>*6*Y$<&#$9&*!",$&%&9&-#*!M6)>*<).9*#,&*!<)$"6-*H."$&#1*<.)*Y65.)6#.)1*

D&>$"$-&4*G-*@ABUF*I3I*,.-.)&>*,&)*/&6>&)C,$;*$-*6>%6-"$-0*#,&*60&-"1_C*JGW[!G3H*)&C;.-C&*M$#,*#,&*,$0,/1*;)&C#$0$.(C*E$//$69*I4*E6#C.-F*])4*D&>6/*.<*R8"&//&-"&F*

#,&*,$0,&C#*,.-.)*5&C#.M&>*51*#,&*I3I4*

7$)8*)&"&$%&>*,&)*9&>$"6/*>&0)&&*<).9*#,&*J&)C,&1*H",../*.<*D&>$"$-&F*'&--C1/%6-$6*H#6#&*^-$%&)C$#14*H,&*#)6$-&>*$-*$-#&)-6/*9&>$"$-&*6->*56C$"*6->*"/$-$"6/*

$99(-./.01*6#*#,&*E6/#&)*P&&>*!)91*D&>$"6/*I&-#&)*6->*#,&*Z6#$.-6/*G-C#$#(#&C*.<*J&6/#,4*7$)8*$C*5.6)>*"&)#$<$&>*$-*$-#&)-6/*9&>$"$-&F*6//&)01*6->*$99(-./.01F*

6->*>$60-.C#$"*6->*"/$-$"6/*/65.)6#.)1*$99(-./.014*H,&*,6C*;(5/$C,&>* .%&)*@@A*96-(C")$;#C*$-*;&&)2)&%$&M&>*K.()-6/CF*6(#,.)&>*-&6)/1*6*>.d&-*",6;#&)C*$-*

C"$&-#$<$"*;(5/$"6#$.-CF*6C*M&//*6C*>&%&/.;&>*6->*;6#&-#&>*%6""$-&C4*

*

*

(4)

!"#$%&'()&*+&",-./.01*2*3)4*3&5.)6,*7$)8*!--.(-"&9&-#*:*!9;/$<$"6#$.-*=($>&*?*@A@B*

*

!"#$%&'()&*+&",-./.0$&C* ****************************************************************************************U* ************************* ** D6)",*@A@B*

*

0;;"'3%>$C%(>/)'2/D*!

!

"#$%&$'&(!%)!'*+,!-./!$)0!.1/!2!,++34566777809*3'*:8;*<64,6=3>?@,AB#CD7?3)6"""E9BF7G;H'0IFJ/;K=C&7I$L0&MK!!

Please include ©@A@B*!"#$%&'()&*+&",-./.01*6-1M,&)&*1.(*961*(C&*#,&C&*,&6>C,.#C*

!!!!!!!!! !

!"#$%&'()*%+,(-.!.(/$01%*2'3(4/3*5"67%"(8"/'9$:$21(;<;=('*2'(%">(?( !"#$%&'()*%+,(-.!.(/$01%*2'3(4/3*5"67%"(8"/'9$:$21(;<;=('*2'(%">(;(

(

!"#$%&'()*%+,(-.!.(/$01%*2'3(4/3*5"67%"(8"/'9$:$21(;<;=('*2'(%">(=(

(

(5)

!"#$%&'()&*+&",-./.01*2*3)4*3&5.)6,*7$)8*!--.(-"&9&-#*:*!9;/$<$"6#$.-*=($>&*?*@A@B*

*

!"#$%&'()&*+&",-./.0$&C* ****************************************************************************************V* ************************* ** D6)",*@A@B*

*

(

E%F$012+3%45"%$G'8'D*!

!

.&($4(!<$N(!4A9(!O*A!$9(!A4%)P!+,(!<*4+!;A99()+!";+%#(.A9(!Q(;,)*&*PO!R*P*5!

,++34566777809*3'*:8;*<64,6;'JN=B*)PKASTDT6""U/V?WXJ0N>'Y;1D,&"9C#C$L0&MK!!

!

!

!

!

!

!

! !

(6)

DALLAS (March 12, 2021) Deborah Birx, M.D., a physician, scien�fic researcher and former White House Coronavirus Coordinator, will join Dallas-

based. Ac�vePure Technologies as Chief Medical and Scien�fic Advisor, the company’s CEO, Joseph Urso, announced today. Ac�vePure is a global provider of air and surface products that destroy the COVID-19 virus and other pathogens in the air and on surfaces, using a unique, patented technology.

“I am pleased to be joining Ac�vePure Technologies, a company that provides a cri�cal layer of protec�on against this virus and other pathogens,” said Birx.

“My work for Ac�vePure is a logical extension of my 40-year career in science and public service. Ac�vePure is a company rooted in science, and I will be doing my best to con�nue to save lives and ensure Americans are safe at school, with their families, at work and in recrea�on.”

“Dr. Birx, one of the highest-ranking infec�ous disease experts in the world, understands the value of Ac�vePure Technology. As a globally recognized health care expert, we are fortunate to have Dr. Birx join our team,” said Joe Urso, CEO of Ac�vePure Technologies. “We are at a pivotal moment with COVID-19.

Americans want to get back to work, back to school and back to normal, but we also want to be safe. The fastest and best way to help keep people safe indoors

is with Ac�vePure. Dr. Birx’s unique perspec�ves and experience will help elevate our science-backed, medical-grade technology and bring it to all indoor spaces.”

In December, the University of Texas Medical Branch confirmed that the Ac�vePure Technology inside two of the company’s devices destroys over 99.9% of airborne COVID-19 viruses within three minutes. In September, the Aerus Hydroxyl Blaster with Ac�vePure Technology demonstrated in an FDA-compliant laboratory MRI Global, destroys 93% of COVID-19 viruses on surfaces in three hours and over 99.9% in seven hours.

In December, the University of Texas Medical Branch confirmed that the Ac�vePure Technology inside two of the company’s devices destroys over 99.9% of airborne COVID-19 viruses within three minutes. In September, the Aerus Hydroxyl Blaster with Ac�vePure Technology demonstrated in an FDA-compliant laboratory MRI Global, destroys 93% of COVID-19 viruses on surfaces in three hours and over 99.9% in seven hours.

As America begins to scale back their statewide safety mandates, many companies, schools, restaurants, and places of worship are con�nuing to enforce protocols from the U.S. Centers for Disease Control and Preven�on. They include reducing capacity and requiring face masks for the safety and comfort of all.

Americans want to return to their normal lives and rou�nes, but the only way to ensure peace of mind is to do so with added layers of protec�on such as

Ac�vePure Technology. Dr. Birx joined the brand because she trusts and believes that its Ac�vePure Technology is the solu�on.

(7)

Ac�vePure Technology, backed by science, is the fastest-ac�ng, most powerful surface and air disinfec�ng purifier available that is safe for use in occupied spaces. It is the only technology that works immediately, in real-�me. The brand, whose roots first began with NASA, has more than 100 devices that contain Ac�vePure, including portable, installed, and hand-held units. The portable units allow customers to operate Ac�vePure within minutes by simply plugging the device into a wall socket. Most Ac�vePure solu�ons cost about $1 a square foot for the areas they protect.

Birx, a re�red Army physician who rose to the rank of colonel, has served three presidents: George W. Bush, Barack Obama, and Donald Trump. As U.S. Global AIDS Coordinator for seven years, she headed the President’s Emergency Plan for AIDS Relief, the largest global health program launched by a single na�on in history. She has published over 220 manuscripts in peer-reviewed journals and authored nearly a dozen chapters in scien�fic publica�ons.

Birx also joined the George W. Bush Ins�tute in Dallas as a fellow in global health.

To learn more about the Ac�vePure Technology, its uses and scien�fic studies, please call 888-217-4316 or contact your Ac�vePure Distributor.

ABOUT ACTIVEPURE TECHNOLOGIES, LLC:

Privately held Ac�vePure Technologies, LLC, is the global leader in ac�ve, con�nuous surface and air disinfec�on systems for health care and educa�onal

ins�tu�ons, commercial and public facili�es, and hospitality and residen�al applica�ons, since 1924. Ac�vePure Technologies includes the patented Ac�ve-

Pure Technology, the most powerful surface and air purifica�on technology ever discovered that is backed by science. With origins in the NASA program, it has been

honored and recognized in the Space Founda�on Hall of Fame for the impact it has had on mankind. Ac�vePure Technology has evolved to reduce exposure to

airborne and surface diseases, including RNA and DNA viruses including the COVID-19 virus, bacteria and molds by more than 99.9%.

(8)

We have an exci�ng announcement to share with you at Ac�vePure Technologies! Deborah Birx, M.D., physician, scien�fic researcher, and former White House

Coronavirus Coordinator has joined Ac�vePure Technologies as our new Chief Medical and Science Advisor.

With an extensive background in global health diplomacy, Dr. Birx is one of the highest-ranking infec�ous disease experts in the world. She has published over 220 manuscripts in peer-reviewed journals and authored nearly a dozen chapters in scien�fic publica�ons. The desire to con�nue her efforts to provide solu�ons for the health and safety of the public aligns with Ac�vePure Technologies’ mission to ensure indoor spaces are protected against viruses, pathogens, and contaminants. With scien�fic support and research, Dr. Birx understands the value of Ac�vePure Technology and its ability to lead us back to normalcy a�er the COVID-19 pandemic and beyond.

Dr. Birx is a re�red Army physician who rose to the rank of colonel and has served three presidents: George W. Bush, Barack Obama, and Donald Trump. While serving under former-Presidents George W. Bush and Barack Obama, she carried out her role as U.S. Global AIDS Coordinator for seven years. While doing so, she headed the President’s Emergency Plan for AIDS Relief—the largest global health program launched by a single na�on in history.

In this video, Dr. Birx shared why she chose to join Ac�vePure Technologies - because she believes and trusts in our flagship technology, Ac�vePure Technology.

We are excited to welcome Dr. Birx as a trusted advisor. We know her unique perspec�ve based on data and years of experience will be a valuable addi�on to our team, and we are thrilled to see what the future holds for us going forward. With Dr. Birx, we believe in the possibili�es of providing science-based and medical-grade technology to consumers looking to protect themselves, their employees, families, homes, businesses and more.

This is an exci�ng �me for Ac�vePure Technologies, and we look forward this new journey with Dr. Birx and her exper�se.

Ac�vePure Technology is working to get the world safely back to work, school, restaurants, concerts, events, gatherings and life before COVID-19.

Wishing you good health,

NAME ORGANIZATION NAME - LOCATION EMAIL

PHONE

(9)
(10)

!"#$%&'()&*+&",-./.01*2*3)4*3&5.)6,*7$)8*!--.(-"&9&-#*:*!9;/$<$"6#$.-*=($>&*?*@A@B*

*

!"#$%&'()&*+&",-./.0$&C* ****************************************************************************************BA* ************************* ** D6)",*@A@B*

*

0;;"'3%>$B'1+(7$A%>+($="(;)+1/D**

!

$

% $

$

(11)

!"#$%&'()&*+&",-./.01*2*3)4*3&5.)6,*7$)8*!--.(-"&9&-#*:*!9;/$<$"6#$.-*=($>&*?*@A@B*

*

!"#$%&'()&*+&",-./.0$&C* ****************************************************************************************B@* ************************* ** D6)",*@A@B*

*

% %

!"#$%J'%344#,5*2%K/2*,%>*7,:#9*7%

E&*,6%&*")&6#&>*#M.*%$>&.C*#.*;).9.#&*#,&*3)4*7$)8*!--.(-"&9&-#4* $

* !"#$*+",$B)("%/$S)R$B)%$T'+.%>$012+3%45"%$6%1).'7'8+%/O*,##;CO[[1.(#(45&[PR7,<@3Z5RM**

T'%$K"/'$(.>$!"#$*+",$!+/15//$6)%+"$4(//+'.$(.>$M+/+'.$<'"$012+3%45"%$6%1).'7'8RD$ILDGZ=*HLLZ*#.*.()*s.(+(5&*I,6--&/* *

$

$

!'F.7'(>D$,++34566777809*3'*:8;*<64,6,O(+(?%CK9*>,:B6""Z.U<[C;\N.]>XF:^GF?4?]$L0&MK!!

! ! ! !

!

!

!

!

*

!"#$!%&'"()$*+",$!+-./--%-$0%"$1%2$3'4%$56$5.6+7%8/"%$

9%.):'4';<$=8>$?+4%$

!"#$!%&'"()$*+",$(:@$5.6+7%8/"%$9%.):'4';<$ABCD$E'%$F"-'D$@+-./--$

)%"$:%2$"'4%$

G(7(+4(&4%$HIJKILMLJ$':$'/"$N'/9/&%$.)(::%4O *

References

Related documents

shapes of the AGN and star formation IR SEDs (see blue dashed and red solid curves in Fig. 2 ), which results in sources with a signif- icant contribution from the AGN component

The rhetoric of the supremacy of the ‘golden coin’ of free markets and democracy championed by Johnson in his vision for Global Britain and future engagement with Africa

The current research describes the adaptation of an informant-rating instrument (the Extreme Demand Avoid- ance Questionnaire; O’Nions et al. 2014b ; EDA-Q) for use as a

The purpose of this study was to examine the perceptions of diagnostic medical sonography online program directors concerning traditional classroom education versus online

This Service Level Agreement (SLA or Agreement) document describes the general scope and nature of the services the Company will provide in relation to the System Software (RMS

A synthetic jet flow which has a wide range of flow field features including high velocity gradients and regions of high vorticity was used as a rigorous test bed to determine

Another study found female gender, obesity, diabetes complication and comorbidities were associated with lower HRQL, among 784 T1D adults (Coffey et al.,2002).Women appear

Other factors that favor good performance in adult cochlear implant candi- dates include lip-reading ability and residual hearing before implantation (patients with some hearing in